Sodium Butyrate and Panobinostat Induce Apoptosis of Chronic Myeloid Leukemia Cells Via Multiple Pathways

Overview

Journal Mol Genet Genomic Med

Specialty Genetics

Date 2019 Mar 21

PMID 30891950

Citations 8

Authors

Xiaoyuan Jia

Yinsuo Zheng

Yanzi Guo

Kan Chen

Affiliations

Soon will be listed here.

Abstract

Purpose: Histone deacetylase inhibitor (HDACI) is a novel therapeutic option for cancer. However, the effects of HDACIs on chronic myeloid leukemia (CML) and the underlying mechanisms are still unknown. The aim of this study was to investigate the effect and the mechanism-of-action of two HDACI members, sodium butyrate (NaBu) and panobinostat (LBH589) in K562 and the adriamycin-resistant cell line K562/ADR.

Methods: Cell viability was assessed using MTT assay. Cell apoptosis was detected with flow cytometry. Cell cycle analysis and western blot were performed to explore the possible molecules related to HDACIs effects.

Results: The effect of NaBu was more powerful on K562/ADR than on K562 cells. LBH589 triggered apoptosis and inhibited the growth of K562 cells. Both HDACIs inhibited K562 and K562/ADR cells via activation of intrinsic/extrinsic apoptotic pathways and inhibition of AKT-mTOR pathway while NaBu also activated endoplasmic reticulum stress (ERS) mediated apoptotic pathway in K562/ADR cells. LBH589 reduced the expression of drug-resistant related proteins in K562 cells. However, neither NaBu nor LBH589 could significantly influence the expression of the drug-resistant related proteins in K562/ADR cells.

Conclusion: The combination of HDACI and other therapeutic strategies are likely required to overcome drug resistance in CML therapy.

Citing Articles

Histone deacetylase inhibitors for leukemia treatment: current status and future directions.

Hosseini M, Sanaat Z, Akbarzadeh M, Vaez-Gharamaleki Y, Akbarzadeh M Eur J Med Res. 2024; 29(1):514.

PMID: 39456044 PMC: 11515273. DOI: 10.1186/s40001-024-02108-8.

Sodium Butyrate (NaB) and Sodium Propionate (NaP) Reduce Cyclin A2 Expression, Inducing Cell Cycle Arrest and Proliferation Inhibition of Different Breast Cancer Subtypes, Leading to Apoptosis.

Ibrahim J, El-Hakim S, Semaan J, Ghosn S, El Ayoubi H, Elnar A Biomedicines. 2024; 12(8).

PMID: 39200243 PMC: 11351769. DOI: 10.3390/biomedicines12081779.

Postbiotics are a candidate for new functional foods.

Wei L, Wang B, Bai J, Zhang Y, Liu C, Suo H Food Chem X. 2024; 23:101650.

PMID: 39113733 PMC: 11304867. DOI: 10.1016/j.fochx.2024.101650.

Epigenetics, Microbiota, and Breast Cancer: A Systematic Review.

Soldado-Gordillo A, Isabel Alvarez-Mercado A Life (Basel). 2024; 14(6).

PMID: 38929688 PMC: 11204553. DOI: 10.3390/life14060705.

HDAC inhibitor chidamide overcomes drug resistance in chronic myeloid leukemia with the T315i mutation through the Akt-autophagy pathway.

Yin L, Zhang Q, Xie S, Cheng Z, Li R, Zhu H Hum Cell. 2023; 36(4):1564-1577.

PMID: 37222919 DOI: 10.1007/s13577-023-00919-1.

References

West K, Castillo S, Dennis P . Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat. 2003; 5(6):234-48. DOI: 10.1016/s1368-7646(02)00120-6. View

Laplante M, Sabatini D . mTOR signaling in growth control and disease. Cell. 2012; 149(2):274-93. PMC: 3331679. DOI: 10.1016/j.cell.2012.03.017. View

Scheffer G, Wijngaard P, Flens M, Izquierdo M, Slovak M, Pinedo H . The drug resistance-related protein LRP is the human major vault protein. Nat Med. 1995; 1(6):578-82. DOI: 10.1038/nm0695-578. View

Li G, Margueron R, Hu G, Stokes D, Wang Y, Reinberg D . Highly compacted chromatin formed in vitro reflects the dynamics of transcription activation in vivo. Mol Cell. 2010; 38(1):41-53. PMC: 3641559. DOI: 10.1016/j.molcel.2010.01.042. View

Li L, Zhang G, Zhang Y, Tan J, Huang H, Huang B . Sodium butyrate-induced upregulation of p18( INK4C ) gene affects K562 cell G (0)/G (1) arrest and differentiation. Mol Cell Biochem. 2008; 319(1-2):9-15. DOI: 10.1007/s11010-008-9870-x. View

Mao Q, Unadkat J . Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update. AAPS J. 2014; 17(1):65-82. PMC: 4287283. DOI: 10.1208/s12248-014-9668-6. View

Hermanson D, Das S, Li Y, Xing C . Overexpression of Mcl-1 confers multidrug resistance, whereas topoisomerase IIβ downregulation introduces mitoxantrone-specific drug resistance in acute myeloid leukemia. Mol Pharmacol. 2013; 84(2):236-43. PMC: 3716322. DOI: 10.1124/mol.113.086140. View

Eckschlager T, Plch J, Stiborova M, Hrabeta J . Histone Deacetylase Inhibitors as Anticancer Drugs. Int J Mol Sci. 2017; 18(7). PMC: 5535906. DOI: 10.3390/ijms18071414. View

Minucci S, Pelicci P . Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006; 6(1):38-51. DOI: 10.1038/nrc1779. View

10.

Marks P, Xu W . Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem. 2009; 107(4):600-8. PMC: 2766855. DOI: 10.1002/jcb.22185. View

11.

Siddiqui W, Ahad A, Ahsan H . The mystery of BCL2 family: Bcl-2 proteins and apoptosis: an update. Arch Toxicol. 2015; 89(3):289-317. DOI: 10.1007/s00204-014-1448-7. View

12.

Benedetti R, Conte M, Altucci L . Targeting Histone Deacetylases in Diseases: Where Are We?. Antioxid Redox Signal. 2014; 23(1):99-126. PMC: 4492558. DOI: 10.1089/ars.2013.5776. View

13.

Zaman G, Flens M, van Leusden M, de Haas M, Mulder H, Lankelma J . The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci U S A. 1994; 91(19):8822-6. PMC: 44698. DOI: 10.1073/pnas.91.19.8822. View

14.

Chu F, Chou P, Zheng X, Mirkin B, Rebbaa A . Control of multidrug resistance gene mdr1 and cancer resistance to chemotherapy by the longevity gene sirt1. Cancer Res. 2005; 65(22):10183-7. DOI: 10.1158/0008-5472.CAN-05-2002. View

15.

Stojanovic N, Hassan Z, Wirth M, Wenzel P, Beyer M, Schafer C . HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer. Oncogene. 2016; 36(13):1804-1815. DOI: 10.1038/onc.2016.344. View

16.

Raphael J, Desautels D, Pritchard K, Petkova E, Shah P . Phosphoinositide 3-kinase inhibitors in advanced breast cancer: A systematic review and meta-analysis. Eur J Cancer. 2018; 91:38-46. DOI: 10.1016/j.ejca.2017.12.010. View

17.

Crisanti M, Wallace A, Kapoor V, Vandermeers F, Dowling M, Pereira L . The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer. Mol Cancer Ther. 2009; 8(8):2221-31. PMC: 3605895. DOI: 10.1158/1535-7163.MCT-09-0138. View

18.

Matsuda Y, Yamauchi T, Hosono N, Uzui K, Negoro E, Morinaga K . Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells. Cancer Sci. 2016; 107(7):1029-38. PMC: 4946706. DOI: 10.1111/cas.12965. View

19.

Ji M, Li J, Yu H, Ma D, Ye J, Sun X . Simultaneous targeting of MCL1 and ABCB1 as a novel strategy to overcome drug resistance in human leukaemia. Br J Haematol. 2009; 145(5):648-56. DOI: 10.1111/j.1365-2141.2009.07678.x. View

20.

Li A, Liu Z, Li M, Zhou S, Xu Y, Xiao Y . Correction: HDAC5, a potential therapeutic target and prognostic biomarker, promotes proliferation, invasion and migration in human breast cancer. Oncotarget. 2017; 8(18):30619-30620. PMC: 5444771. DOI: 10.18632/oncotarget.17542. View